MECHANISM OF ACTION

Targeting F508del-CFTR brings more active CFTR proteins to the cell surface1

DEFECTIVE F508del-CFTR PROTEIN

DEFECTIVE F508del-CFTR PROTEIN diagram
  • Patients with an F508del-CFTR mutation have decreased CFTR activity at the cell surface2

TEZACAFTOR and IVACAFTOR

TEZACAFTOR and IVACAFTOR diagram
  • Tezacaftor improves cellular processing and trafficking of F508del-CFTR proteins1
  • Ivacaftor potentiates the channel-open probability of CFTR proteins at the cell surface1

ELEXACAFTOR, TEZACAFTOR, and IVACAFTOR

ELEXACAFTOR, TEZACAFTOR, and IVACAFTOR diagram
  • Binding to a different site than tezacaftor, elexacaftor has an additive effect in improving cellular processing and trafficking of F508del-CFTR proteins1

TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) is approved for patients with CF aged 12 years and older with at least one F508del mutation1

CFTR, cystic fibrosis transmembrane conductance regulator.